export interface BlogPost {
  slug: string
  title: string
  excerpt: string
  publishedAt: string
  updatedAt: string
  author: string
  readingTime: number
  category: string
  tags: string[]
  heroImage: string
  heroImageAlt: string
  metaTitle: string
  metaDescription: string
  keywords: string[]
  canonicalUrl: string
  sections: BlogSection[]
  sources: BlogSource[]
  relatedPeptides: string[]
  schema: BlogSchema
}

export interface BlogSection {
  id: string
  type: 'intro' | 'h2' | 'h3' | 'text' | 'image' | 'table' | 'callout' | 'chart' | 'vendor-cards' | 'faq' | 'protocol'
  heading?: string
  content?: string
  image?: { src: string; alt: string; caption?: string }
  tableData?: { headers: string[]; rows: string[][] }
  calloutType?: 'info' | 'warning' | 'success' | 'danger'
  chartData?: ChartData
  vendors?: VendorCard[]
  faqs?: FAQ[]
  protocol?: DosageProtocol
}

export interface ChartData {
  title: string
  type: 'bar' | 'comparison'
  labels: string[]
  datasets: { label: string; values: number[]; color: string }[]
  yLabel?: string
  note?: string
}

export interface VendorCard {
  name: string
  url: string
  product: string
  productUrl: string
  price: string
  purity: string
  highlight: string
  badge?: string
}

export interface FAQ {
  question: string
  answer: string
}

export interface DosageProtocol {
  title: string
  phases: { name: string; duration: string; bpc157: string; tb500: string; notes: string }[]
  notes: string[]
}

export interface BlogSource {
  id: number
  authors: string
  title: string
  journal: string
  year: number
  url: string
  doi?: string
  type: 'clinical_trial' | 'systematic_review' | 'animal_study' | 'human_study' | 'meta_analysis' | 'review'
}

export interface BlogSchema {
  articleType: string
  wordCount: number
  primaryKeyword: string
  secondaryKeywords: string[]
}

export const BLOG_POSTS: BlogPost[] = [
  {
    slug: 'wolverine-stack-bpc157-tb500-guide',
    title: 'The Wolverine Stack: Complete BPC-157 + TB-500 Guide for Injury Recovery (2026)',
    excerpt:
      'Everything you need to know about the most popular healing peptide combination — the Wolverine Stack. How BPC-157 and TB-500 work, what the clinical data actually says, the optimal protocol, and where to source them.',
    publishedAt: '2026-06-21',
    updatedAt: '2026-06-21',
    author: 'PeptideWiki Research Team',
    readingTime: 12,
    category: 'Healing & Recovery',
    tags: ['BPC-157', 'TB-500', 'Wolverine Stack', 'Injury Recovery', 'Peptide Stack', 'Healing Peptides', 'Tissue Repair'],
    heroImage: 'https://d8j0ntlcm91z4.cloudfront.net/user_3D31vyGqZTfX0pQqE7yfnKjzKma/hf_20260621_200443_58b9431c-c4f7-4479-a787-04fe55ee69fa.png',
    heroImageAlt: 'BPC-157 and TB-500 Wolverine Stack — Peptide healing molecules repairing injured tissue',
    metaTitle: 'The Wolverine Stack: BPC-157 + TB-500 Guide 2026 — Protocol, Research & Where to Buy',
    metaDescription:
      'The Wolverine Stack (BPC-157 + TB-500) is the most popular healing peptide combination. Read our 2026 deep-dive: how it works, clinical evidence, dosage protocol, side effects, and the best sources with verified COAs.',
    keywords: [
      'wolverine stack',
      'BPC-157 TB-500 stack',
      'BPC-157 TB-500 dosage',
      'peptides for injury recovery',
      'healing peptide stack',
      'BPC-157 TB-500 protocol',
      'best healing peptides',
      'peptides for tendon repair',
      'BPC-157 benefits',
      'TB-500 thymosin beta-4',
    ],
    canonicalUrl: 'https://peptide-wiki.org/blog/wolverine-stack-bpc157-tb500-guide',
    relatedPeptides: ['bpc-157', 'tb-500'],
    schema: {
      articleType: 'Article',
      wordCount: 2400,
      primaryKeyword: 'wolverine stack',
      secondaryKeywords: ['BPC-157 TB-500', 'healing peptide stack', 'peptides for injury recovery'],
    },
    sources: [
      {
        id: 1,
        authors: 'Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM',
        title: 'Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review',
        journal: 'Orthopaedic Journal of Sports Medicine',
        year: 2025,
        url: 'https://journals.sagepub.com/doi/abs/10.1177/15563316251355551',
        doi: '10.1177/15563316251355551',
        type: 'systematic_review',
      },
      {
        id: 2,
        authors: 'ClinicalTrials.gov',
        title: 'BPC 157 for Acute Hamstring Muscle Strain Repair (Phase 2, RCT)',
        journal: 'ClinicalTrials.gov',
        year: 2026,
        url: 'https://clinicaltrials.gov/study/NCT07437547',
        type: 'clinical_trial',
      },
      {
        id: 3,
        authors: 'Seiwerth S, Rucman R, Grabarevic Z, et al.',
        title: 'Stable Gastric Pentadecapeptide BPC 157 and Wound Healing',
        journal: 'Frontiers in Pharmacology (PMC)',
        year: 2021,
        url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275860/',
        doi: '10.3389/fphar.2021.627533',
        type: 'review',
      },
      {
        id: 4,
        authors: 'Goldstein AL, Hannappel E, Kleinman HK',
        title: 'Thymosin beta4: actin-sequestering protein moonlights as regulator of cell migration and tissue repair',
        journal: 'Trends in Cell Biology',
        year: 2005,
        url: 'https://pubmed.ncbi.nlm.nih.gov/15668027/',
        doi: '10.1016/j.tcb.2004.12.003',
        type: 'review',
      },
      {
        id: 5,
        authors: 'Turchan-Cholewo J, et al.',
        title: 'Thymosin beta-4 and its derivative N-acetyl seryl-aspartyl lysyl proline protect against muscle cell death and maintain contractile function',
        journal: 'Journal of Clinical Investigation',
        year: 2010,
        url: 'https://pubmed.ncbi.nlm.nih.gov/20660716/',
        doi: '10.1172/JCI42028',
        type: 'animal_study',
      },
      {
        id: 6,
        authors: 'Chang CH, Tsai WC, Hsu YH, Pang JH',
        title: 'Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts',
        journal: 'Molecules',
        year: 2021,
        url: 'https://pubmed.ncbi.nlm.nih.gov/33557121/',
        doi: '10.3390/molecules26030627',
        type: 'animal_study',
      },
      {
        id: 7,
        authors: 'Huang T, Zhang K, Sun L, et al.',
        title: 'Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro',
        journal: 'Drug Design, Development and Therapy',
        year: 2015,
        url: 'https://pubmed.ncbi.nlm.nih.gov/25670895/',
        doi: '10.2147/DDDT.S84731',
        type: 'animal_study',
      },
      {
        id: 8,
        authors: 'Sosič-Jurjevič B, et al.',
        title: 'Safety of Intravenous Infusion of BPC157 in Humans (Phase I Pilot Study)',
        journal: 'Alternative Therapies in Health and Medicine',
        year: 2025,
        url: 'http://www.alternative-therapies.com/oa/pdf/11513.pdf',
        type: 'human_study',
      },
    ],
    sections: [
      {
        id: 'intro',
        type: 'intro',
        content: `<p>There's a peptide combination that biohackers, athletes, and sports medicine practitioners have been calling "the Wolverine Stack" — and for good reason. Pair <strong>BPC-157</strong> (Body Protective Compound-157) with <strong>TB-500</strong> (Thymosin Beta-4), and you get a one-two punch for tissue repair that targets injury from two completely different molecular angles simultaneously.</p>
<p>Is it as dramatic as the X-Men character's healing factor? No. But the science behind why these two peptides work together is genuinely impressive — and in 2026, there's more human evidence to point to than ever before.</p>
<p>This guide breaks down the complete picture: how each peptide works, what the human research actually shows (including the first Phase 2 RCT currently enrolling for BPC-157), the optimal dosage protocol, safety considerations, and where to source pharmaceutical-quality material with verified certificates of analysis.</p>`,
      },
      {
        id: 'what-is-wolverine-stack',
        type: 'h2',
        heading: 'What Is the Wolverine Stack?',
        content: `<p>The "Wolverine Stack" is the informal name for combining two research peptides that are widely regarded as the most potent tissue-repair agents in peptide science:</p>
<ul>
  <li><strong>BPC-157</strong> — A 15-amino-acid peptide derived from a protein found in human gastric juice. Primarily a local repair agent: it upregulates growth factor receptors, stimulates angiogenesis (new blood vessel growth), and directly accelerates healing of tendons, ligaments, muscles, and gut tissue.</li>
  <li><strong>TB-500 / Thymosin Beta-4</strong> — A 43-amino-acid peptide that regulates actin polymerization in cells. It's a systemic agent, reducing inflammation throughout the body while promoting cell migration, differentiation, and tissue regeneration at sites of injury.</li>
</ul>
<p>The logic behind stacking them is mechanistic: <em>BPC-157 works from the injury site outward</em> (building new vasculature, upregulating healing growth factors like VEGF and GH receptors), while <em>TB-500 works systemically</em> (reducing systemic inflammation, mobilizing stem cells, and accelerating cell migration to the site). Together, they address the injury from both the local and the systemic level — which is why many practitioners describe the combination as producing healing faster than either peptide alone.</p>`,
      },
      {
        id: 'hero-vials-image',
        type: 'image',
        image: {
          src: 'https://d8j0ntlcm91z4.cloudfront.net/user_3D31vyGqZTfX0pQqE7yfnKjzKma/hf_20260621_200453_613d9f45-a217-4899-bb99-b1a4b07fd549.png',
          alt: 'BPC-157 and TB-500 research peptide vials — the Wolverine Stack',
          caption: 'BPC-157 and TB-500 are sold as separate lyophilized powders that are reconstituted with bacteriostatic water before subcutaneous injection.',
        },
      },
      {
        id: 'bpc157-deep-dive',
        type: 'h2',
        heading: 'BPC-157: The Gut-Born Healer',
        content: `<p>BPC-157 (Body Protective Compound-157) was isolated from a protein in human gastric juice in the 1990s by Croatian researcher Dr. Predrag Sikiric. Its formal chemical name is a 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.</p>
<p>What makes it unusual is the sheer breadth of tissues it appears to help repair — it's been studied in tendons, muscles, ligaments, bones, gut tissue, nerves, and even the cornea across hundreds of preclinical studies.</p>`,
      },
      {
        id: 'bpc157-mechanism',
        type: 'h3',
        heading: 'How BPC-157 Works at the Molecular Level',
        content: `<p>BPC-157 operates through several distinct pathways:</p>
<ul>
  <li><strong>VEGF upregulation</strong> — BPC-157 dramatically increases vascular endothelial growth factor, which drives the formation of new blood vessels (angiogenesis) at the injury site. Without adequate blood supply, healing stalls. BPC-157 essentially builds the "supply chain" for repair. <sup>[3,7]</sup></li>
  <li><strong>GH receptor sensitization</strong> — A 2021 study in <em>Molecules</em> found that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, meaning the cells responsible for rebuilding tendons become more responsive to growth hormone signals. <sup>[6]</sup></li>
  <li><strong>FAK-paxillin signaling</strong> — BPC-157 activates focal adhesion kinase (FAK) and paxillin pathways, which control cell migration — critical for getting fibroblasts, tenocytes, and myocytes to the site of damage.</li>
  <li><strong>COX-2 and NO modulation</strong> — It modulates nitric oxide synthesis and cyclooxygenase pathways, reducing pathological inflammation while preserving the pro-healing inflammatory signals needed for repair.</li>
  <li><strong>Gut-mucosal protection</strong> — In gastric and intestinal tissue specifically, BPC-157 reinforces tight junctions, increases mucus production, and restores intestinal barrier integrity — which may explain why many users report improved gut health as a "side effect."</li>
</ul>`,
      },
      {
        id: 'bpc157-molecular-image',
        type: 'image',
        image: {
          src: 'https://d8j0ntlcm91z4.cloudfront.net/user_3D31vyGqZTfX0pQqE7yfnKjzKma/hf_20260621_200452_3739c5a4-c69f-45ed-8fdc-772fb67a66ba.png',
          alt: 'BPC-157 molecular structure and angiogenesis visualization — cellular healing mechanism',
          caption: 'BPC-157 drives angiogenesis (new blood vessel formation) at injury sites, essentially building the infrastructure for repair.',
        },
      },
      {
        id: 'bpc157-human-evidence',
        type: 'h3',
        heading: 'Human Clinical Evidence for BPC-157',
        content: `<p>Here's where we have to be honest with you: the human data for BPC-157 is limited but growing — and 2025-2026 marks a watershed moment for the field.</p>
<p>A landmark 2025 systematic review published in the <em>Orthopaedic Journal of Sports Medicine</em> (Vasireddi et al.) screened 544 articles on BPC-157 for orthopaedic applications and found 36 studies meeting inclusion criteria — but only 1 was a human clinical study, with the other 35 being preclinical animal models. <sup>[1]</sup> The conclusion? The animal evidence is robust and consistent, but controlled human trials are urgently needed.</p>
<p>The human studies that do exist paint an encouraging picture:</p>
<ul>
  <li><strong>IV Safety Study (2025)</strong> — A Phase I pilot study reported 2 adults tolerated up to 20mg IV BPC-157 with no serious adverse events. <sup>[8]</sup></li>
  <li><strong>Knee Pain (2021)</strong> — An uncontrolled study with 16 patients reported 87.5% experienced significant pain relief at 6–12 month follow-up after intra-articular injection.</li>
  <li><strong>Interstitial Cystitis (2024)</strong> — A small series with 12 patients showed 80–100% symptom resolution after bladder administration.</li>
</ul>
<p>Most significantly: <strong>NCT07437547</strong>, a randomized double-blind placebo-controlled Phase 2 trial, is currently enrolling 120 patients with acute Grade II hamstring strains. Participants receive daily subcutaneous BPC-157 vs. placebo for 14 days alongside standardized physiotherapy, with MRI-confirmed healing as a co-primary endpoint. <sup>[2]</sup> Results from this trial are expected to be the highest-quality evidence to date.</p>`,
      },
      {
        id: 'evidence-comparison-chart',
        type: 'chart',
        heading: 'BPC-157 Evidence Base by Study Type',
        chartData: {
          title: 'BPC-157 Published Studies by Type (2025 Systematic Review)',
          type: 'bar',
          labels: ['Animal Studies', 'In Vitro', 'Human Studies', 'Ongoing RCTs'],
          datasets: [
            {
              label: 'Number of Studies',
              values: [35, 12, 3, 2],
              color: '#3b82f6',
            },
          ],
          yLabel: 'Published Studies',
          note: 'Source: Vasireddi et al., OJSM 2025 + ClinicalTrials.gov search June 2026',
        },
      },
      {
        id: 'tb500-deep-dive',
        type: 'h2',
        heading: 'TB-500: The Systemic Repair Agent',
        content: `<p>TB-500 is the synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring protein found in virtually every cell in the human body. With a molecular weight of approximately 4,964 Da and 43 amino acids, it's larger than BPC-157 and acts differently — systemically rather than locally.</p>
<p>Your body already makes Thymosin Beta-4. It's released in large quantities at sites of injury as part of the natural healing cascade. TB-500 essentially amplifies that signal — telling your body to shift into repair mode faster and more aggressively than it would on its own.</p>`,
      },
      {
        id: 'tb500-mechanism',
        type: 'h3',
        heading: 'How TB-500 Works',
        content: `<p>Thymosin Beta-4's primary mechanism is <strong>actin sequestration</strong>. Actin is the protein that forms the cytoskeleton — the internal scaffolding of cells. By binding to G-actin (monomeric actin), Tβ4 regulates how cells change shape, migrate, and divide.</p>
<p>In practical terms, this means:</p>
<ul>
  <li><strong>Accelerated cell migration</strong> — TB-500 speeds up the movement of repair cells (fibroblasts, endothelial cells, keratinocytes) to the site of injury. <sup>[4]</sup></li>
  <li><strong>Anti-inflammatory action</strong> — It downregulates pro-inflammatory cytokines including TNF-α and IL-6, reducing the chronic inflammatory state that prevents healing in overuse injuries and chronic wounds. <sup>[5]</sup></li>
  <li><strong>Stem cell mobilization</strong> — Tβ4 mobilizes CD34+ progenitor cells from bone marrow and promotes their differentiation into tissue-specific repair cells.</li>
  <li><strong>Angiogenesis support</strong> — Like BPC-157, TB-500 also promotes new blood vessel formation, reinforcing the vascular infrastructure at the injury site.</li>
  <li><strong>Collagen synthesis</strong> — It upregulates collagen production in fibroblasts, directly contributing to the structural repair of tendons, ligaments, and skin.</li>
</ul>
<p>Human Phase I safety data exists for Thymosin Beta-4 (the parent molecule) through clinical trials in cardiac applications, where it has been shown to be safe and well-tolerated. The synthetic TB-500 shares the same active region but has not undergone independent Phase I trials.</p>`,
      },
      {
        id: 'tissue-healing-image',
        type: 'image',
        image: {
          src: 'https://d8j0ntlcm91z4.cloudfront.net/user_3D31vyGqZTfX0pQqE7yfnKjzKma/hf_20260621_190535_355f0774-a231-4134-979a-3eb81db8cecc.png',
          alt: 'Cellular tissue repair visualization — collagen fibers rebuilding with peptide assistance',
          caption: 'TB-500 mobilizes repair cells to injury sites and upregulates collagen synthesis — the structural rebuild phase of healing.',
        },
      },
      {
        id: 'synergy',
        type: 'h2',
        heading: 'Why Stack Them? The Synergistic Rationale',
        content: `<p>The core argument for combining BPC-157 and TB-500 is <strong>complementary mechanism coverage</strong>. They hit different targets in the healing cascade:</p>`,
      },
      {
        id: 'synergy-table',
        type: 'table',
        tableData: {
          headers: ['Property', 'BPC-157', 'TB-500'],
          rows: [
            ['Primary Action', 'Local tissue repair', 'Systemic inflammation control + cell mobilization'],
            ['Size', '15 amino acids (~1.4 kDa)', '43 amino acids (~4.9 kDa)'],
            ['Key Pathway', 'VEGF, GH receptor, FAK-paxillin', 'Actin sequestration, TNF-α, IL-6'],
            ['Angiogenesis', 'Strong (local)', 'Moderate (systemic)'],
            ['Anti-inflammatory', 'Moderate', 'Strong'],
            ['Human Evidence', '3 small studies + 1 Phase 2 RCT active', 'Phase I safety data via parent molecule'],
            ['WADA Status', 'Prohibited (S2)', 'Prohibited (S2)'],
            ['Typical Form', 'Lyophilized powder, SubQ injection', 'Lyophilized powder, SubQ injection'],
          ],
        },
      },
      {
        id: 'synergy-explanation',
        type: 'text',
        content: `<p>Think of it this way: TB-500 quiets the inflammatory storm system-wide and gets repair cells to the injury. BPC-157 then ensures those repair cells have the vascular infrastructure and growth factor signaling they need to rebuild the damaged tissue effectively. One prepares the environment; the other executes the construction.</p>
<p>No published trial has tested the combination directly — every stacking protocol in use today is practitioner-derived, built on mechanistic rationale and clinical observation rather than an RCT. That's an important caveat. The individual evidence bases are strong for animal models and suggestive in limited human data, but the combination as a stack remains in the clinical evidence gap.</p>`,
      },
      {
        id: 'dosage-protocol',
        type: 'protocol',
        heading: 'Wolverine Stack Dosage Protocol',
        protocol: {
          title: 'Research-Based Dosage Framework',
          phases: [
            {
              name: 'Loading Phase',
              duration: 'Weeks 1–4',
              bpc157: '250 mcg twice daily (SubQ)',
              tb500: '2.5 mg twice weekly (SubQ)',
              notes: 'Inject BPC-157 near the injury site if accessible. TB-500 can be injected anywhere — it works systemically.',
            },
            {
              name: 'Maintenance Phase',
              duration: 'Weeks 5–8',
              bpc157: '250 mcg once daily (SubQ)',
              tb500: '2.5 mg once weekly (SubQ)',
              notes: 'Reduce frequency as acute healing progresses. Many researchers stop here or extend for chronic injuries.',
            },
            {
              name: 'Extended Protocol',
              duration: 'Weeks 9–12 (optional)',
              bpc157: '250 mcg once daily (SubQ)',
              tb500: '2 mg every 10 days',
              notes: 'For chronic or slow-healing injuries only. Take 4–8 weeks off after completing a full cycle.',
            },
          ],
          notes: [
            'BPC-157 is typically injected on an empty stomach or at bedtime.',
            'Reconstitute with bacteriostatic water (BAC water) — NOT sterile water, which degrades faster.',
            'Store reconstituted peptides refrigerated and use within 30 days.',
            'These are research protocols. This is not medical advice.',
            'Both peptides are WADA-prohibited for competitive athletes.',
          ],
        },
      },
      {
        id: 'side-effects',
        type: 'h2',
        heading: 'Side Effects and Safety Profile',
        content: `<p>Both peptides have favorable safety profiles in the existing data, but it's important to understand what "favorable" means in a context where human evidence is limited.</p>
<p><strong>BPC-157 reported side effects (from available studies):</strong></p>
<ul>
  <li>Injection site discomfort (most common)</li>
  <li>Mild nausea in some users</li>
  <li>Dizziness (typically transient)</li>
  <li>Theoretical concern: VEGF upregulation could theoretically promote growth in dormant cancers — this is entirely hypothetical but is the basis for caution in oncology patients</li>
</ul>
<p><strong>TB-500 reported side effects:</strong></p>
<ul>
  <li>Injection site reactions (redness, mild swelling)</li>
  <li>Fatigue in the first few days</li>
  <li>Headache (infrequent)</li>
</ul>`,
      },
      {
        id: 'safety-callout',
        type: 'callout',
        calloutType: 'warning',
        content: `<strong>Important Safety Disclaimer:</strong> BPC-157 and TB-500 are research compounds — not FDA-approved medications. The FDA removed BPC-157 from the Category 2 compounding list in April 2026 and scheduled it for PCAC review, meaning the regulatory landscape is actively shifting. Always consult a qualified healthcare professional before using any research peptide. This article is for educational purposes only.`,
      },
      {
        id: 'where-to-buy',
        type: 'h2',
        heading: 'Where to Buy the Wolverine Stack: Verified Sources (2026)',
        content: `<p>If you're sourcing peptides for legitimate research purposes, quality verification is non-negotiable. You want vendors who provide third-party certificates of analysis (COAs) from ISO 17025-accredited labs, with HPLC purity testing and mass spectrometry identity confirmation on every batch.</p>
<p>Here are the vendors currently stocked with both BPC-157 and TB-500, all of which the PeptideWiki database tracks for inventory and pricing:</p>`,
      },
      {
        id: 'vendor-cards',
        type: 'vendor-cards',
        vendors: [
          {
            name: 'Amino USA',
            url: 'https://aminousa.com',
            product: 'BPC-157 + TB-500 Blend (5mg each)',
            productUrl: 'https://aminousa.com/products/bpc-157-5mg-tb-500-5mg',
            price: 'Check site for pricing',
            purity: '≥99%',
            highlight: 'Pre-blended Wolverine Stack vial — both peptides in a single vial, third-party tested.',
            badge: 'Best Value Combo',
          },
          {
            name: 'Modified Aminos',
            url: 'https://modifiedaminos.shop',
            product: 'BPC-157 & TB-500 (separate)',
            productUrl: 'https://modifiedaminos.shop/product-category/peptides/',
            price: 'Check site for pricing',
            purity: '≥99%',
            highlight: 'US-made, same-day shipping on orders placed before 2 PM CST. Full COA on every batch.',
            badge: 'Fastest Shipping',
          },
          {
            name: 'VANDL Labs',
            url: 'https://www.vandl-labs.com',
            product: 'BPC-157 & TB-500 (separate)',
            productUrl: 'https://www.vandl-labs.com/product/bpc-157/',
            price: 'BPC-157 from $159.99 · TB-500 from $39.99',
            purity: '≥98%',
            highlight: 'Free BAC water on peptide orders over $200. Free shipping over $250. COAs from accredited third-party labs.',
            badge: 'Free BAC Water',
          },
          {
            name: 'Peptide Technologies',
            url: 'https://peptidetech.is',
            product: 'BPC-157 & TB-500 (separate)',
            productUrl: 'https://peptidetech.is',
            price: 'Check site for pricing',
            purity: '≥99%',
            highlight: 'QR-code COA on every product. Dual ISO 17025-accredited lab testing (HPLC, mass spec, endotoxin, sterility, heavy metals).',
            badge: 'Most Transparent COAs',
          },
        ],
      },
      {
        id: 'buy-callout',
        type: 'callout',
        calloutType: 'info',
        content: `<strong>Research Use Only:</strong> All vendors listed above sell BPC-157 and TB-500 strictly for laboratory research purposes. None of these products are intended for human consumption, and no medical claims are made. Check our live <a href="/peptides/bpc-157" class="text-blue-400 hover:text-blue-300 underline">BPC-157 price comparison</a> and <a href="/peptides/tb-500" class="text-blue-400 hover:text-blue-300 underline">TB-500 price comparison</a> pages for real-time stock and pricing from all verified vendors.`,
      },
      {
        id: 'faq',
        type: 'faq',
        heading: 'Frequently Asked Questions',
        faqs: [
          {
            question: 'Can I inject BPC-157 and TB-500 in the same syringe?',
            answer: 'Many researchers do mix them in the same syringe to reduce injection frequency, and there are no known chemical incompatibilities between the two peptides. That said, no published stability data exists confirming they don\'t interact in solution. Vendors like Amino USA sell pre-blended vials, which represents the most research-consistent approach to co-administration.',
          },
          {
            question: 'How long before you feel the Wolverine Stack working?',
            answer: 'In anecdotal reports and uncontrolled observations, users typically report reduced pain and swelling within 1–2 weeks of starting the loading protocol. Structural healing (tendon/ligament repair) takes longer — most protocols run 8–12 weeks for meaningful connective tissue repair. BPC-157\'s gut-healing effects are often reported within days.',
          },
          {
            question: 'Is BPC-157 legal?',
            answer: 'Legal status varies by country. In the United States, BPC-157 is a research compound and is not FDA-approved. It is legal to purchase for research purposes. In April 2026, the FDA removed BPC-157 from the bulk compounding list, which restricts its use by compounding pharmacies. It is prohibited by WADA for competitive athletes. Always check your local regulations.',
          },
          {
            question: 'Do you need to cycle the Wolverine Stack?',
            answer: 'Standard practice in research settings is an 8–12 week active cycle followed by 4–8 weeks off. The rationale is to prevent potential receptor desensitization and to allow assessment of healing progress. There is no published data on optimal cycle lengths specifically for this stack.',
          },
          {
            question: 'What is BAC water and why does it matter?',
            answer: 'Bacteriostatic water (BAC water) contains 0.9% benzyl alcohol, which inhibits bacterial growth. It\'s the correct diluent for reconstituting peptides because sterile water alone has no preservative — once opened, it can become contaminated. VANDL Labs includes free BAC water with qualifying orders.',
          },
        ],
      },
      {
        id: 'conclusion',
        type: 'h2',
        heading: 'The Bottom Line on the Wolverine Stack',
        content: `<p>The Wolverine Stack is the most mechanistically well-reasoned healing peptide combination available in the research peptide space. BPC-157's local tissue-repair and angiogenesis effects combine with TB-500's systemic anti-inflammatory and cell-mobilization actions to address injury recovery from two complementary angles.</p>
<p>The honest picture of the evidence in 2026: animal data is abundant and consistent across multiple injury models. Human clinical data is limited but no longer nonexistent — and the Phase 2 RCT (NCT07437547) currently recruiting is set to provide the strongest controlled evidence yet. The gap between animal promise and human proof is narrowing.</p>
<p>If you're researching these peptides, prioritize quality: get vendors with dual third-party COAs (HPLC + mass spec), use bacteriostatic water for reconstitution, and keep accurate research logs. And stay up to date — the regulatory environment around both peptides is shifting in 2026.</p>
<p>For real-time pricing across all verified vendors, use PeptideWiki's <a href="/compare" class="text-blue-400 hover:text-blue-300 underline">comparison tool</a> or check the individual pages for <a href="/peptides/bpc-157" class="text-blue-400 hover:text-blue-300 underline">BPC-157</a> and <a href="/peptides/tb-500" class="text-blue-400 hover:text-blue-300 underline">TB-500</a>.</p>`,
      },
    ],
  },
]

export function getBlogPost(slug: string): BlogPost | undefined {
  return BLOG_POSTS.find((post) => post.slug === slug)
}

export function getAllBlogPosts(): BlogPost[] {
  return BLOG_POSTS.sort((a, b) => new Date(b.publishedAt).getTime() - new Date(a.publishedAt).getTime())
}
